by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
Australian Journal of Pharmacy : November 2006
product news ethical products otc products Bladder treatment A RROW Pharmaceuticals has launched Vesicare (solifenacin succi- nate) a once-daily medication for the treatment of overactive bladder. Vesicare is effective across all symptoms of overactive bladder including urgency, frequency and urge incontinence. In two 12-week placebo-controlled trials, patients were found to have a reduction in their urgency episodes of more than 50 per cent. In a 40-week open-label extension of two 12-week placebo-controlled trials, the average number of incontinence episodes per 24 hours decreased by 66 per cent, while 60 per cent of all extension patients with more than one episode of incontinence per 24 hours were totally dry at the study endpoint. Improvements in major symptoms of overactive bladder were noted for up to 52 weeks, and patients had high satisfaction with tolerability (85 per cent) and efficacy (74 per cent). Vesicare is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency. www.arrowpharma.com.au ¦ Call for hep-B awareness figures revealing that more than 30 per cent of those with hepatitis B are undiagnosed. The call coincided with the Government’s decision to list Pegasys (peginterferon alfa-2a) on the PBS for the treatment of hepatitis B from 1 October. Pegasys, the first once-weekly inter- A feron treatment to treat chronic hepatitis, includes a key ingredient (peginterferon alfa-2a) which can modify the body’s immune system response to help fight infections and severe diseases. ¦ 54 ? THE AUSTRALIAN JOURNAL OF PHARMACY VOL 87 NOVEMBER 2006 USTRALIAN clinicians are calling for more hepatitis B screenings, with New-look chesty cough tablets O GI Diary for diabetes P EOPLE with diabetes can now use a new management tool, the Accu-Chek GI (Glycaemic Index) Diary, to help them see how certain foods affect their blood glucose levels (BGLs). Along with regular blood glucose monitoring, appropriate eating habits play a crucial role in diabetes manage-ment as different carbohydrate foods have varying impacts on the levels of blood glucose. The Accu-Chek GI Diary has been developed by Roche Diagnostics Australia, in collaboration with dietitian Jane Barnes, to complement the Accu-Chek range of blood glucose meters and encourage people with diabetes to better manage their diet and BGLs by monitoring the quantity and the GI component of foods they eat. www.accu-chek.com ¦ New indication for drops A new indication for Nurofen for Children Infant Drops has been approved: the drops are now approved for infants from three months of age. This brings Australia in line with 18 other countries, including the UK, France and Ireland, where Nurofen for Children is approved for use in children from this age. The concentrated formula of Nurofen for Children Infant Drops means that babies and young children do not need to swallow as much liquid for an effective dose to be administered. Nurofen for Children Infant Drops has a pleasant strawberry flavour and is packaged in a convenient 30mL bottle, administered using an easy-to-use dosing device. www.nurofen.com.au ¦ VER the coming months, Bisolvon Chesty Tablets 8mg will receive a new look! The tablets’ packaging is changing, from plastic bottles to new blister foil packaging, for the 50s and 100s packs. The new packaging will be more consumer- friendly and convenient, and has been designed for people on the go. Bisolvon Chesty Tablets are indicated for adults and children over the age of six; they contain bromhexine hydrochloride, which thins mucus and aids expectoration. This allows the natural cough response to clear the chest. www.Bisolvon.com.au ¦